AstraZeneca company went all in with a seemingly groundbreaking study. However, the results were utterly disappointing. The organization was looking at a combination of two immunotherapy drugs to help patients combat lung cancer. This illness is the most vicious one of them all, surpassing the combined death toll of prostate, breast, and colorectal cancers. Nonetheless, the crucial lung cancer trial failed to help their patients.
The Clinical Lung Cancer Trial Didn’t Ensure Patients a Certain Point of Progression-Free Survival Benefit
On Thursday, British company AstraZeneca announced some negative results on their most important drug study so far called MYSTIC. The team of scientists worked at a drug combination between durvalumab and tremelimumab as a cure for lung cancer. However, the results didn’t live up to expectations. The new treatment proved to be no more effective than chemotherapy.
The patients selected for the study had their tumors with a PD-L1 protein developed on at least 25% throughout their cancer cells. On top of that, the company was also working on a secondary treatment called Imfinzi. This monotherapy recorded catastrophic evolution. That’s because patients couldn’t reach a certain point of progression-free survival benefit.
The British company saw this clinical trial as a pivotal addition to the value of its new drug portfolio. Chief Executive Pascal Soriot has been keeping the hope high as these results were only the initial readout. Therefore, he calls for patience and sees how the MYSTIC lung cancer trial continues to develop at the following stages.
All Players in the Pharmaceutical Industry Are Racing to Obtain Patent on the Ideal Immunotherapies
Immunotherapies are the latest Holy Grail within the pharmaceutical industry. They are the only ones that can influence the immune system to fight tumors harder than they usually do. As a consequence, competitors are now racing against the clock to develop the first viable treatment. With lung cancer doing most damages, this market offers the highest opportunity to companies.
AstraZeneca was still recovering after a drug sales drop due to its loss of patents on successful products such as Crestor. Therefore, the revenue during the first quarter fell 10% to $5.05 billion. Analysts expect a second-quarter revenue of $5.0 billion.
Image source: 1